Return to homepagePandemic Pact

NIAID-VRC-Research, Development, and Production to Support Ebola Bispecific Antibody Development

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N91019D00024-0-759102200015-1

Grant search

Key facts

  • Disease

    Ebola

  • Start & end year

    2022
    2027

  • Known Financial Commitments (USD)

    $2,765,029

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    CHRIS CASE

  • Research Location

    United States of America

  • Lead Research Institution

    LEIDOS BIOMEDICAL RESEARCH, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The NIAID mission and scope includes rapidly responding to infectious disease outbreaks and preparing for future pandemics through clinical product development, reagent production, and manufacturing. In following this mission, the VRC has prioritized development of vaccines and antibodies targeting Ebola that may lead to prevention and/or therapeutic treatment. Specifically, the VRC seeks to develop and manufacture Ebola bispecific antibody products.